Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.
Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in the development of immunoglobulin E (IgE) antibodies designed to treat cancer, focusing on solid tumors. Epsilogen's portfolio includes IgE candidates that target specific cancer antigens such as HER2, EGFR, and PD-L1. The company also has an IgE platform that facilitates the development and manufacturing validation of novel antibodies. By leveraging the unique properties of IgE, Epsilogen aims to enhance tumor access and increase the potency of cancer treatments, thereby improving therapeutic outcomes for patients.
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
Curve Therapeutics Limited is a drug-discovery company based in London, United Kingdom, founded in 2019. The company focuses on developing technologies to target currently undruggable disease-modifying targets, with a primary emphasis on cancer. Curve has created an innovative screening platform that allows for the functional screening of genetically encoded Microcycle™ libraries against a variety of disease-associated targets in their native conformation within mammalian cells. This platform is designed to facilitate the discovery of first-in-class therapeutics, enabling the development of a pipeline of novel cancer drugs. By targeting challenging cancer interactions, including intracellular protein-protein and protein-gene interactions, Curve Therapeutics aims to deliver advanced treatments for complex cancer-related conditions.
Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.
Harness Therapeutics is a biotechnology company dedicated to developing a novel class of therapeutic RNAs known as SINEUPs®, which allow for precise upregulation of protein expression. This innovative technology provides a unique mechanism of action aimed at addressing challenging diseases, significantly broadening the druggable proteome. Harness Therapeutics focuses on central nervous system and ophthalmologic disorders but also sees potential applications across various therapeutic areas. By enhancing translation, their platform meets unmet medical needs and enables the creation of differentiated products that cannot be achieved with existing technologies.
Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.
Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in the development of immunoglobulin E (IgE) antibodies designed to treat cancer, focusing on solid tumors. Epsilogen's portfolio includes IgE candidates that target specific cancer antigens such as HER2, EGFR, and PD-L1. The company also has an IgE platform that facilitates the development and manufacturing validation of novel antibodies. By leveraging the unique properties of IgE, Epsilogen aims to enhance tumor access and increase the potency of cancer treatments, thereby improving therapeutic outcomes for patients.
Dunad Therapeutics is a biopharmaceutical company dedicated to developing innovative targeted protein degradation therapies. The company utilizes a small molecule platform that induces the selective degradation of disease-causing and often difficult-to-target proteins by directly modulating their stability and conformation. This approach offers a novel molecular strategy that is adaptable and operates through a mechanism of action that is not limited to specific target classes, distinguishing it from existing targeted protein degradation technologies. By focusing on oral therapies, Dunad Therapeutics aims to provide effective treatment options for challenging diseases.
Leucid Bio is a biotechnology company focused on developing innovative cell therapies for patients with refractory cancers, particularly solid tumors. Founded to leverage two decades of research from King's College London in the CAR-T field, Leucid Bio is guided by a seasoned management team possessing both scientific and commercial expertise. The company has a strong partnership with King's College, granting it exclusive access to a wealth of scientific, clinical, and manufacturing resources, particularly from Dr. Maher and his team of immuno-oncology specialists. By specializing in advanced CAR T-cell therapies, Leucid Bio aims to enhance treatment outcomes and provide durable responses for patients who have limited or no treatment options available.
Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
RapidPulse, Inc. is a privately held medical device company focused on developing innovative minimally invasive vascular products for the treatment of ischemic stroke. The company's flagship product is the RapidPulse™ Cyclic Aspiration System, which features a novel aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse originated as a spinout from Syntheon LLC, a medical device incubator dedicated to fostering advancements in the industry.
LUNAC Therapeutics is focused on developing advanced oral anticoagulant medications aimed at treating and preventing serious thrombotic events. The company’s innovative drugs are designed to reduce the risk of bleeding in patients, which allows healthcare providers to safely escalate dosages for high-risk individuals. By addressing a critical need in the management of thrombotic conditions, LUNAC Therapeutics aims to improve patient outcomes and enhance the overall safety of anticoagulant therapies.
Dunad Therapeutics is a biopharmaceutical company dedicated to developing innovative targeted protein degradation therapies. The company utilizes a small molecule platform that induces the selective degradation of disease-causing and often difficult-to-target proteins by directly modulating their stability and conformation. This approach offers a novel molecular strategy that is adaptable and operates through a mechanism of action that is not limited to specific target classes, distinguishing it from existing targeted protein degradation technologies. By focusing on oral therapies, Dunad Therapeutics aims to provide effective treatment options for challenging diseases.
Slate Bio is a company focused on developing immunotherapeutics aimed at treating autoimmune and inflammatory diseases. It creates therapies that leverage a bifunctional cytokine to restore the body's natural immunological response. By inducing antigen expression in genes associated with autoimmune conditions, Slate Bio offers a unique approach that provides patients with an independent synergistic pathway. This method is designed to enhance tissue selectivity and improve pharmacodynamics while minimizing the required dosage and potential side effects.
Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2019. The company is dedicated to developing innovative disease-modifying therapeutics aimed at restoring cellular balance in patients suffering from neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. Libra Therapeutics focuses on small molecule drugs that enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Through its distinct molecular approaches, the company aims to address the cellular imbalances that characterize these debilitating conditions, thereby providing potential new treatment options for affected individuals.
Macomics is an immuno-oncology company. Macomics focus on the development of novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.
LUNAC Therapeutics is focused on developing advanced oral anticoagulant medications aimed at treating and preventing serious thrombotic events. The company’s innovative drugs are designed to reduce the risk of bleeding in patients, which allows healthcare providers to safely escalate dosages for high-risk individuals. By addressing a critical need in the management of thrombotic conditions, LUNAC Therapeutics aims to improve patient outcomes and enhance the overall safety of anticoagulant therapies.
Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in the development of immunoglobulin E (IgE) antibodies designed to treat cancer, focusing on solid tumors. Epsilogen's portfolio includes IgE candidates that target specific cancer antigens such as HER2, EGFR, and PD-L1. The company also has an IgE platform that facilitates the development and manufacturing validation of novel antibodies. By leveraging the unique properties of IgE, Epsilogen aims to enhance tumor access and increase the potency of cancer treatments, thereby improving therapeutic outcomes for patients.
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.
AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system. AdoRx’s lead programs are focused on the design of “fit for purpose” adenosine receptor antagonists that will overcome the effects of high adenosine levels. AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. The AdoRx leadership team have discovered in excess of 25 clinical candidates and have greater than 60 years combined experience of drug discovery in biotech and pharma.
Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.
Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in the development of immunoglobulin E (IgE) antibodies designed to treat cancer, focusing on solid tumors. Epsilogen's portfolio includes IgE candidates that target specific cancer antigens such as HER2, EGFR, and PD-L1. The company also has an IgE platform that facilitates the development and manufacturing validation of novel antibodies. By leveraging the unique properties of IgE, Epsilogen aims to enhance tumor access and increase the potency of cancer treatments, thereby improving therapeutic outcomes for patients.
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.
Mironid Limited is a drug discovery company based in Newhouse, United Kingdom, focused on developing targeted therapies for degenerative kidney diseases, chronic inflammatory diseases, and cancer. Established in 2014, Mironid specializes in creating novel drug candidate molecules by modulating the activity of key cell signaling proteins. Its drug discovery pipeline includes innovative compounds aimed at treating chronic inflammatory diseases and degenerative kidney diseases. The company employs a unique Physiology Mirroring Approach, designing assays that replicate the conformation and environment of drug targets as found in living cells. By focusing on unmet medical needs, Mironid aims to advance its drug development programs, particularly those targeting cAMP-degrading phosphodiesterase enzymes, ultimately striving to deliver effective and differentiated therapies to market.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological capabilities. Its lead product candidate, TPM203, is currently undergoing clinical testing for pemphigus vulgaris, an orphan disease. Additional programs are being developed for conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. Topas Therapeutics has established research and collaboration agreements with notable partners, including Eli Lilly and Company and Boehringer Ingelheim, to advance its innovative approaches to immune tolerance. The company aims to address significant unmet medical needs by promoting immune tolerance to blood-borne antigens.
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
Caldan Therapeutics Ltd is a spinout company from the University of Glasgow (UofG) and the University of Southern Denmark (SDU), developing novel therapeutics targeting modulators of free fatty acid receptors, for metabolic disease including Type 2 Diabetes (T2D) and other indications. The spinout opportunity has arisen from a long term collaboration between Professor Graeme Milligan (UofG) and Professor Trond Ulven (SDU). Free fatty acid receptors have recently emerged as exciting targets for T2D, due to their involvement in multiple aspects of T2D pathophysiology. There may also be potential to explore other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.
CLS is a drug discovery company focusing on rational drug design to discover and develop mechanistically novel kinase inhibitors for use in both human and animal health care. CLS’s kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation. Unlike many other kinase inhibitor programs, however, CLS is targeting novel binding sites (on kinase targets that have proved challenging) as well as previously “un-drugged” kinases. Driving CLS success in this effort is a team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development. CLS provides this team with the opportunity to pursue strategies and targets outside Pharma’s traditional focus. In addition, scientific and business collaborations are being established to enable the success of the business. The strategy is to develop and maintain a program pipeline: discover, develop, partner, repeat.
Funderbeam is a global funding and trading platform established in 2013, designed to connect companies and investors for the buying and selling of equity stakes. The platform facilitates investments in early-stage and growth companies, providing founders with exposure, legal support, and access to an investor network. Investors benefit from the ability to manage their investments actively and trade at their discretion. Utilizing blockchain technology, Funderbeam enhances transparency and security in transactions, allowing clients to track their private market portfolios effectively. This innovative approach positions Funderbeam as a key player in the ecosystem of startup funding and investment.
Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.
Clyde Biosciences specializes in developmental drug testing, focusing on cardiac cell analysis solutions. The company offers a platform that generates human-relevant functional data from cardiomyocytes, which aids in understanding the mechanisms and actions of drugs in development. By providing insights into drug performance at earlier stages, Clyde Biosciences aims to reduce risks associated with the development of new medicines.
Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, founded in 2014. It focuses on the research and development of innovative therapies for respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to create disease-modifying therapies that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increased susceptibility to lung infections. By developing these novel treatments, Enterprise Therapeutics seeks to enhance the quality of life for patients suffering from these chronic respiratory conditions.
Sirakoss is a medical device company based in Scotland that specializes in the development of synthetic bone graft substitutes. The company focuses on creating innovative solutions for trauma, spine, craniomaxillofacial, and dental applications. Sirakoss is advancing its proprietary MaxSi™ Graft technology, which is available in granular and putty forms. This technology is designed to facilitate the fusion of bones, addressing various conditions including congenital and degenerative issues. By providing effective treatment options, Sirakoss aims to enhance patient recovery and support a return to healthy lifestyles.
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.
CLS is a drug discovery company focusing on rational drug design to discover and develop mechanistically novel kinase inhibitors for use in both human and animal health care. CLS’s kinase inhibitors target key signal transduction enzymes involved in the regulation of cancer growth and survival, or in the modulation of chronic inflammation. Unlike many other kinase inhibitor programs, however, CLS is targeting novel binding sites (on kinase targets that have proved challenging) as well as previously “un-drugged” kinases. Driving CLS success in this effort is a team of world-class experts with extensive Pharma experience in kinase inhibitor discovery and development. CLS provides this team with the opportunity to pursue strategies and targets outside Pharma’s traditional focus. In addition, scientific and business collaborations are being established to enable the success of the business. The strategy is to develop and maintain a program pipeline: discover, develop, partner, repeat.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, established in 2014. The company focuses on image-guided therapy to detect, diagnose, and monitor diseases, primarily through its innovative molecular imaging technology. This technology employs fluorescent imaging to identify diseases in real-time during interventional procedures such as surgery. Initially, Edinburgh Molecular Imaging developed fluorescent optical imaging agents like EMI-137 for cancer detection and surgical guidance, achieving significant progress in clinical trials. In 2019, the company shifted its focus towards therapeutics, leveraging its expertise in systemic radiotherapy targeting c-Met to create a radiotheragnostic pair. The company has successfully completed proof-of-concept studies and has initiated clinical development, supported by a team with extensive experience in imaging agent discovery, medicinal chemistry, biochemistry, and cell biology, as well as knowledge of regulatory approvals and commercialization in the US and EU markets.